Technical Assistance - Siemens IMMULITE 2000 C-Peptide Mode D'emploi

Masquer les pouces

Table Des Matières

Table des Matières

Les langues disponibles

(PST) = 0.94 (Serum) + 0.45 ng/mL

r = 0.99

n = 43

Means:

5.3 ng/mL (Serum)

5.6 ng/mL (Heparin)

5.4 ng/mL (PST)

(SST) = 0.99 (Plain tubes) + 0.15 ng/mL

r = 0.99

n = 42

Means:

5.1 ng/mL (Serum)

5.2 ng/mL (SST)

Method Comparison–Serum: The assay

was compared to IMMULITE 2000

C-Peptide (L2KPE) procedure on 89

serum samples. (Concentration range:

approximately 1.2 – 6.9 ng/mL. See graph

1.) By linear regression:

(IML 2000 L2KPEP) = 0.94 (IML 2000 L2KPE) –

0.30 ng/mL

r = 0.923

Means:

2.9 ng/mL (IMMULITE 2000 L2KPEP)

3.4 ng/mL (IMMULITE 2000 L2KPE)

Method Comparison–Urine: The assay

was compared to IMMULITE 2000

C-Peptide (L2KPE) procedure on 87 urine

samples. (Concentration range:

approximately 0.6 – 6.9 ng/mL. See graph

2.) By linear regression:

(IML 2000 L2KPEP) = 1.01 (IML 2000 L2KPE) –

0.33 ng/mL

r = 0.969

Means:

3.3 ng/mL (IMMULITE 2000 L2KPEP)

3.6 ng/mL (IMMULITE 2000 L2KPE)

References

1) Beischer W. Proinsulin and C-peptide in

humans. In: Fotherby K, Pal S, editors.

Hormones in Normal and Abnormal Human

Tissues. Vol 3. Berlin: Walter DeGruyter, 1983:

1-43. 2) Beyer J, Krause U, Cordes U. C-

peptide: its biogenesis, structure, determination

and clinical significance. Giornale Ital Chem Clin

1979;4 Suppl 1:9-22. 3) Bonser A, Garcia-Webb

P. C-Peptide measurement: methods and

clinical utility. CRC Crit Rev Clin Lab Sci

1984;19:297-352. 4) Gonen G, Rubenstein AH,

Horwitz DL, Blix PM. Clinical significance of C-

peptide. In: Baba S, Kaneko T, Yanaihara N,

editors. Proinsulin, Insulin, C-Peptide.

Amsterdam: Excerpta Medica, 1979: 246-53.

5) Horwitz D, et al. Proinsulin, insulin and C-

peptide concentrations in human portal and

peripheral blood. J Clin Invest 1975;55:1278-83.

6) Horwitz D, Kuzuya H, Rubenstein AH.

Circulating serum C-peptide. N Engl J Med

1976;295:207-9. 7) Polonsky KS, Rubenstein

AH. C-peptide as a measure of the secretion

and hepatic extraction of insulin; pitfalls and

limitations. Diabetes 1984;33:486-93.

8) Rendell M. Expanding clinical use of C-

peptide radioimmunoassay. Acta Diabetol Lat

1983;20:105-13. 9) Rubenstein AH, Kuzuya H,

Horwitz DL. Clinical significance of circulating C-

peptide in diabetes mellitus and hypoglycemic

disorders. Arch Intern Med 1977;137:625-32.

10) Turkington RW, Estkowski A, Link M.

Secretion of insulin or connecting peptide; a

predictor of insulin dependence of obese

diabetics'. Arch Intern Med 1982;142:1102-5.

11) Data on file. 12) National Committee for

Clinical Laboratory Standards. Procedures for

the collection of diagnostic blood specimens by

venipuncture; approved standard. 4th ed.

NCCLS Document H3-A4, Wayne, PA: NCCLS,

1998. 13) CLSI. Protocols for the Determination

of Limits of Detection and Limits of Quantitation;

Approved Guideline. CLSI document EP17-A

Vol. 24 (No. 34). CLSI, 940 West Valley Road,

Suite 1400, Wayne, Pennsylvania 19087-1898,

USA, 2004. 14) Evaluation of Precision

Performance of Quantitative Measurement

Methods; Approved Guideline-Second Edition.

CLSI document EP5-A2. CLSI, 940 West Valley

Road, Suite 1400 Wayne, Pennsylvania 19087-

1898, USA 2004. 15) Centers for Disease

Control. Update: Universal precautions for

prevention of transmission of human

immunodeficiency virus, hepatitis B virus and

other bloodborne pathogens in healthcare

settings. MMWR, 1988;37:377–82, 387–8.

16) Clinical and Laboratory Standards Institute

(formerly NCCLS). Protection of Laboratory

Workers From Occupationally Acquired

Infections; Approved Guideline - Third Edition.

Wayne, PA: Clinical and Laboratory Standards

Institute; 2005. NCCLS Document M29-A3.

17) Federal Occupational Safety and Health

Administration, Bloodborne Pathogens

Standard, 29 CFR 1910.1030.